SMPD1 and Miyoshi myopathy: Furthermore, Faict and colleagues highlighted that MM cell treatment with melphalan or bortezomib induced the release of EVs with a higher amount of acid sphingomyelinase, which could have a role in the MM drug resistance mechanism [88].